Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-44803-1
Abstract: Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of Parkinson’s disease.… read more here.
Keywords: production; fgf20; targeted repositioning; fibroblast growth ... See more keywords
The effect of 5‐HT1A receptor agonists on the entopeduncular nucleus is modified in 6‐hydroxydopamine‐lesioned rats
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15437
Abstract: l‐DOPA prolonged treatment leads to disabling motor complications as dyskinesia that could be decreased by drugs acting on 5‐HT1A receptors. Since the internal segment of the globus pallidus, homologous to the entopeduncular nucleus in rodents,… read more here.
Keywords: entopeduncular nucleus; ht1a receptor; lesioned rats; hydroxydopamine ... See more keywords
Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
Sign Up to like & getrecommendations! Published in 2018 at "Neural Regeneration Research"
DOI: 10.4103/1673-5374.235076
Abstract: Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson’s disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition.… read more here.
Keywords: hydroxydopamine; rotenone hydroxydopamine; substantia nigra; parkinson disease ... See more keywords